BlackRock Tech and Private Equity Term Stock Price, News & Analysis

Brooklyn ImmunoTherapeutics has expanded its team with new scientific hires and opened a 5,200 square foot R&D facility in San Diego, enhancing its capabilities in cell therapies and genetic medicines. The facility will support translational research and IND-enabling studies, aiming to treat cancer and genetic disorders. The team includes experts with over 12 years in pluripotent stem cell research. Brooklyn's key program, IRX-2, is in Phase 2B trials for head and neck cancer, following promising Phase 2A results.

Brooklyn ImmunoTherapeutics (Nasdaq: BTX) reported its financial results for Q4 and the full year ended December 31, 2021. The company appointed new executives and transitioned to the Nasdaq Global Market while being added to both the Nasdaq and ICE Biotechnology Indexes. In 2021, Brooklyn raised over $52 million and completed the acquisition of Novellus, enhancing its gene therapy platform. For 2021, operating expenses totaled $113.6 million, with a net loss of $122.3 million. Despite increased expenses, cash reserves improved significantly to $17 million by year's end.

Brooklyn ImmunoTherapeutics (Nasdaq: BTX) announced the completion of a private placement, raising approximately $12 million from a leading healthcare investor. The company issued 6,857,142 units at $1.75 per unit, each comprising one share of common stock and a warrant to purchase shares at $1.91 each over five and a half years. Proceeds will support general working capital. The securities sold are subject to resale registration with the SEC.

Brooklyn ImmunoTherapeutics (Nasdaq: BTX) has announced a definitive agreement to sell securities in a private placement, expected to generate approximately $12 million in gross proceeds. The company will issue 6,857,142 units at $1.75 each, each comprising one share of common stock and a warrant at an exercise price of $1.91. The placement is set to close around March 9, 2022. The net proceeds will be used for general working capital. Brooklyn is focused on treatment options for cancer and other diseases through innovative therapies, with ongoing clinical programs.

BROOKLYN, NY, Jan. 20, 2022 – Brooklyn ImmunoTherapeutics (Nasdaq: BTX) has appointed two new members to its Board of Directors: Erin S. Enright and Heather B. Redman. Both bring extensive experience in finance and governance, aiming to enhance the company's strategic direction as it develops therapies for rare diseases. Enright has a strong background in public companies and investment, while Redman has expertise in venture capital and technology. CEO Howard Federoff anticipates that their contributions will strengthen Brooklyn’s position in the biopharmaceutical market.

Brooklyn ImmunoTherapeutics (BTX) announced the issuance of 18 new patents and filing of 17 new patent applications in 2021, all exclusively licensed from Factor Bioscience. These patents cover advances in mRNA-based cellular reprogramming, gene editing, and nucleic acid delivery via ToRNAdo™ lipid nanoparticle technology. With over 70 issued patents and 60 pending applications, Brooklyn is positioned to enhance its therapeutic capabilities in cancer and genetic diseases.

The company’s lead program, IRX-2, shows promise in treating head and neck cancer.

Brooklyn ImmunoTherapeutics (Nasdaq: BTX) has been included in the ICE Biotechnology Index as of December 20, 2021. This inclusion reflects the company's recognition in the biotech sector, according to CEO Howard Federoff. The ICE Biotechnology Index tracks U.S.-listed biotechnology firms engaged in therapeutic research and development. Brooklyn is focused on innovative treatments for cancer, blood disorders, and monogenic diseases, with its lead program, IRX-2, currently in a Phase 2B clinical trial for head and neck cancer, showing promising survival benefits in earlier phases.

Brooklyn ImmunoTherapeutics, Inc. (Nasdaq: BTX) has been named to the Nasdaq Biotechnology Index, effective December 20, 2021. This inclusion signifies recognition of Brooklyn's potential in the biotech sector, as noted by CEO Howard Federoff. The Nasdaq Biotechnology Index tracks the performance of biotechnology and pharmaceutical securities. Brooklyn's advanced program, IRX-2, a human cell-derived cytokine therapy, is in Phase 2B trials for head and neck cancer, building on promising Phase 2A results demonstrating overall survival benefits.

BROOKLYN, Dec. 02, 2021 – Brooklyn ImmunoTherapeutics (Nasdaq: BTX) announced that President and CEO Howard Federoff, M.D., Ph.D. will present at two upcoming virtual conferences. He will speak at the Benzinga Global Small Cap Conference on December 8 at 4:40 PM EST, and at the MedInvest Oncology Investor Conference on December 9 at 11:20 AM EST. Both conferences will offer one-on-one meetings with management. Brooklyn is advancing treatments for cancer and blood disorders, including its human cell-derived therapy IRX-2, currently in Phase 2B trials for head and neck cancer.